With new treatments for Alzheimer’s disease, early diagnosis is vital, and this is where detection of appropriate biomarkers is crucial. Pathology in Practice Science Editor Brian Nation looks at recent published work in this area.
Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings
Palmqvist S, Whitson HE, Allen LA et al. Alzheimers Dement. 2025 Jul; 21 (7): e70535. doi: 10.1002/alz.70535.
A panel of clinicians, subject-matter experts, and guideline methodologists convened by the Alzheimer’s Association conducted a systematic review and formulated evidence-based recommendations for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer’s disease (AD) within specialised care settings. The scope focuses on individuals with objective cognitive impairment, including those with mild cognitive impairment (MCI) or dementia, who are undergoing evaluation by providers trained and experienced in memory disorders, where AD is the suspected underlying aetiology.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.